Single-band Upconversion Nanoprobes for Multiplexed Simultaneous in Situ Molecular Mapping of Cancer Biomarkers
Overview
Authors
Affiliations
The identification of potential diagnostic markers and target molecules among the plethora of tumour oncoproteins for cancer diagnosis requires facile technology that is capable of quantitatively analysing multiple biomarkers in tumour cells and tissues. Diagnostic and prognostic classifications of human tumours are currently based on the western blotting and single-colour immunohistochemical methods that are not suitable for multiplexed detection. Herein, we report a general and novel method to prepare single-band upconversion nanoparticles with different colours. The expression levels of three biomarkers in breast cancer cells were determined using single-band upconversion nanoparticles, western blotting and immunohistochemical technologies with excellent correlation. Significantly, the application of antibody-conjugated single-band upconversion nanoparticle molecular profiling technology can achieve the multiplexed simultaneous in situ biodetection of biomarkers in breast cancer cells and tissue specimens and produce more accurate results for the simultaneous quantification of proteins present at low levels compared with classical immunohistochemical technology.
Surface plasmon polariton-enhanced upconversion luminescence for biosensing applications.
Le D, Kreivi M, Aikio S, Heinilehto N, Sipola T, Petaja J Nanophotonics. 2024; 13(21):3995-4006.
PMID: 39634956 PMC: 11501061. DOI: 10.1515/nanoph-2024-0247.
Lanthanide ion-doped upconversion nanoparticles for low-energy super-resolution applications.
Lamon S, Yu H, Zhang Q, Gu M Light Sci Appl. 2024; 13(1):252.
PMID: 39277593 PMC: 11401911. DOI: 10.1038/s41377-024-01547-6.
Nanometer-resolution tracking of single cargo reveals dynein motor mechanisms.
Peng C, Zhang Y, Liu Q, Marti G, Huang Y, Sudhof T Nat Chem Biol. 2024; .
PMID: 39090313 PMC: 11785820. DOI: 10.1038/s41589-024-01694-2.
Exploiting cell death and tumor immunity in cancer therapy: challenges and future directions.
Lu J, He R, Liu Y, Zhang J, Xu H, Zhang T Front Cell Dev Biol. 2024; 12:1416115.
PMID: 38887519 PMC: 11180757. DOI: 10.3389/fcell.2024.1416115.
Konugolu Venkata Sekar S, Ma H, Komolibus K, Dumlupinar G, Mickert M, Krawczyk K Biomed Opt Express. 2024; 15(2):900-909.
PMID: 38404324 PMC: 10890842. DOI: 10.1364/BOE.504939.